Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase

Amyloid precursor protein (APP) is endoproteolytically processed by BACE1 and γ-secretase to release amyloid peptides (Aβ40 and 42) that aggregate to form senile plaques in the brains of patients with Alzheimer's disease (AD). The C-terminus of Aβ40/42 is generated by γ-secretase, whose activity is dependent upon presenilin (PS 1 or 2). Missense mutations in PS1 (and PS2) occur in patients with early-onset familial AD (FAD), and previous studies in transgenic mice and cultured cell models demonstrated that FAD-PS1 variants shift the ratio of Aβ40 : 42 to favor Aβ42. One hypothesis to explain this outcome is that mutant PS alters the specificity of γ-secretase to favor production of Aβ42 at the expense of Aβ40. To test this hypothesis in vivo, we studied Aβ40 and 42 levels in a series of transgenic mice that co-express the Swedish mutation of APP (APPswe) with two FAD-PS1 variants that differentially accelerate amyloid pathology in the brain. We demonstrate a direct correlation between the concentration of Aβ42 and the rate of amyloid deposition. We further show that the shift in Aβ42 : 40 ratios associated with the expression of FAD-PS1 variants is due to a specific elevation in the steady-state levels of Aβ42, while maintaining a constant level of Aβ40. These data suggest that PS1 variants do not simply alter the preferred cleavage site for γ-secretase, but rather that they have more complex effects on the regulation of γ-secretase and its access to substrates.

[1]  T. Iwatsubo,et al.  The role of presenilin cofactors in the γ-secretase complex , 2003, Nature.

[2]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[3]  Hong Wang,et al.  PEN-2 and APH-1 Coordinately Regulate Proteolytic Processing of Presenilin 1* , 2003, The Journal of Biological Chemistry.

[4]  P. Greengard,et al.  Presenilin-1 Regulates Intracellular Trafficking and Cell Surface Delivery of β-Amyloid Precursor Protein* , 2003, The Journal of Biological Chemistry.

[5]  Hongqiao Li,et al.  Mammalian APH-1 Interacts with Presenilin and Nicastrin and Is Required for Intramembrane Proteolysis of Amyloid-β Precursor Protein and Notch* , 2002, The Journal of Biological Chemistry.

[6]  Harald Steiner,et al.  PEN-2 Is an Integral Component of the γ-Secretase Complex Required for Coordinated Expression of Presenilin and Nicastrin* , 2002, The Journal of Biological Chemistry.

[7]  T. Iwatsubo,et al.  A Role for Presenilin 1 in Regulating the Delivery of Amyloid Precursor Protein to the Cell Surface , 2002, Neurobiology of Disease.

[8]  Alena Savonenko,et al.  Transgenic mouse models of neurodegenerative disease: Opportunities for therapeutic development , 2002, Current neurology and neuroscience reports.

[9]  J. Rietdorf,et al.  Presenilin-1 affects trafficking and processing of βAPP and is targeted in a complex with nicastrin to the plasma membrane , 2002, The Journal of cell biology.

[10]  C. Haass,et al.  Presenilin and nicastrin regulate each other and determine amyloid β-peptide production via complex formation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Borchelt,et al.  Accumulation of proteolytic fragments of mutant presenilin 1 and accelerated amyloid deposition are co-regulated in transgenic mice , 2002, Neurobiology of Aging.

[12]  M. Fortini,et al.  Nicastrin Is Required for γ-Secretase Cleavage of the Drosophila Notch Receptor , 2002 .

[13]  D. St Johnston,et al.  Drosophila nicastrin is essential for the intramembranous cleavage of notch. , 2002, Developmental cell.

[14]  G. Struhl,et al.  Nicastrin is required for Presenilin-mediated transmembrane cleavage in Drosophila , 2001, Nature Cell Biology.

[15]  A. Levey,et al.  Multiple Effects of Aspartate Mutant Presenilin 1 on the Processing and Trafficking of Amyloid Precursor Protein* , 2001, The Journal of Biological Chemistry.

[16]  D. Borchelt,et al.  Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice. , 2001, Human molecular genetics.

[17]  Klaus Fuchs,et al.  Presenilin‐dependent γ‐secretase processing of β‐amyloid precursor protein at a site corresponding to the S3 cleavage of Notch , 2001 .

[18]  P. Lantos,et al.  Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin‐1 gene show an unusual but characteristic β‐amyloid pathology known as ‘cotton wool’ plaques , 2001, Neuropathology and applied neurobiology.

[19]  D. Borchelt,et al.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. , 2001, Biomolecular engineering.

[20]  J. Hardy,et al.  A Pathogenic Presenilin-1 Deletion Causes Abberrant Aβ42 Production in the Absence of Congophilic Amyloid Plaques* , 2001, The Journal of Biological Chemistry.

[21]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[22]  D. Selkoe,et al.  FAD Mutations in Presenilin-1 or Amyloid Precursor Protein Decrease the Efficacy of a γ-Secretase Inhibitor: Evidence for Direct Involvement of PS1 in the γ-Secretase Cleavage Complex , 2000, Neurobiology of Disease.

[23]  R. Rozmahel,et al.  Carboxyl-terminal Fragments of Alzheimer β-Amyloid Precursor Protein Accumulate in Restricted and Unpredicted Intracellular Compartments in Presenilin 1-deficient Cells* , 2000, The Journal of Biological Chemistry.

[24]  Robert A. Copeland,et al.  Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors* , 2000, The Journal of Biological Chemistry.

[25]  A. Paetau,et al.  Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS‐1 mutations that lead to exceptionally high amyloid‐β concentrations , 2000, Annals of neurology.

[26]  Ruedi Aebersold,et al.  Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing , 2000, Nature.

[27]  I. Tesseur,et al.  Modeling Alzheimer's disease in transgenic mice: effect of age and of Presenilin1 on amyloid biochemistry and pathology in APP/London mice , 2000, Experimental Gerontology.

[28]  D. Selkoe,et al.  Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1 , 2000, Nature Cell Biology.

[29]  B. Strooper,et al.  Total inactivation of γ–secretase activity in presenilin-deficient embryonic stem cells , 2000, Nature Cell Biology.

[30]  A. Bernstein,et al.  Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1 , 2000, Nature Cell Biology.

[31]  Min Xu,et al.  Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1 , 2000, Nature.

[32]  C. Haass,et al.  Presenilin-1 differentially facilitates endoproteolysis of the β-amyloid precursor protein and Notch , 2000, Nature Cell Biology.

[33]  H. Soininen,et al.  Identification of a novel 4.6-kb genomic deletion in presenilin-1 gene which results in exclusion of exon 9 in a Finnish early onset Alzheimer's disease family: an Alu core sequence-stimulated recombination? , 2000, European Journal of Human Genetics.

[34]  D. Selkoe,et al.  Cell Surface Presenilin-1 Participates in the γ-Secretase-like Proteolysis of Notch* , 1999, The Journal of Biological Chemistry.

[35]  S. Wagner,et al.  Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice , 1999, Nature Neuroscience.

[36]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[37]  William J. Ray,et al.  A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.

[38]  D. Selkoe,et al.  Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. , 1998, Biochemistry.

[39]  D. Borchelt,et al.  Effects of PS1 Deficiency on Membrane Protein Trafficking in Neurons , 1998, Neuron.

[40]  T. Iwatsubo,et al.  Mutant Presenilin 2 Transgenic Mouse: Effect on an Age‐Dependent Increase of Amyloid β‐Protein 42 in the Brain , 1998, Journal of neurochemistry.

[41]  A. Paetau,et al.  A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1 , 1998, Nature Medicine.

[42]  Hugo Vanderstichele,et al.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.

[43]  D. Selkoe,et al.  A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's γ-Secretase Activity , 1998 .

[44]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[45]  C. L. Harris,et al.  Evidence That Levels of Presenilins (PS1 and PS2) Are Coordinately Regulated by Competition for Limiting Cellular Factors* , 1997, The Journal of Biological Chemistry.

[46]  D. Borchelt,et al.  Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.

[47]  K. Duff.  Alzheimer transgenic mouse models come of age , 1997, Trends in Neurosciences.

[48]  D. Borchelt,et al.  Hyperaccumulation of FAD-linked presenilin 1 variants in vivo , 1997, Nature Medicine.

[49]  H. Mori,et al.  Increased Aβ 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS-1 gene , 1997, Neuroscience Letters.

[50]  T. Iwatsubo,et al.  The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[52]  D L Price,et al.  A vector for expressing foreign genes in the brains and hearts of transgenic mice. , 1996, Genetic analysis : biomolecular engineering.

[53]  Allan I. Levey,et al.  Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.

[54]  B. Greenberg,et al.  Enhanced Amyloidogenic Processing of the β-Amyloid Precursor Protein in Gene-targeted Mice Bearing the Swedish Familial Alzheimer's Disease Mutations and a “Humanized” Aβ Sequence* , 1996, The Journal of Biological Chemistry.

[55]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[56]  J. Rommens,et al.  Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. , 1996, Human molecular genetics.

[57]  M. Adams,et al.  A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene , 1995, Neuroreport.

[58]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[59]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[60]  S. Younkin,et al.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). , 1995, The Journal of biological chemistry.

[61]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[62]  S. Squazzo,et al.  Evidence that production and release of amyloid beta-protein involves the endocytic pathway. , 1994, The Journal of biological chemistry.

[63]  D. Selkoe,et al.  Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. , 1994, The Journal of biological chemistry.

[64]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[65]  R. Tanzi,et al.  Expression of a ubiquitous, cross-reactive homologue of the mouse beta-amyloid precursor protein (APP). , 1994, The Journal of biological chemistry.

[66]  M J Ball,et al.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[67]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[68]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[69]  S. Younkin,et al.  Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. , 1993, Science.

[70]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[71]  P. Lansbury,et al.  Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. , 1992, Biochemistry.

[72]  S. Estus,et al.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing. , 1992, Science.

[73]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[74]  C. Cotman,et al.  Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. , 1992, The Journal of biological chemistry.

[75]  D. Kukuruga,et al.  Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[76]  A. Hirano,et al.  A COMPARATIVE STUDY OF MODIFIED BIELSCHOWSKY, BODIAN AND THIOFLAVIN S STAINS ON ALZHEIMER'S NEUROFIBRILLARY TANGLES , 1986, Neuropathology and applied neurobiology.

[77]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[78]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[79]  A. Hirano,et al.  Alzheimer's neurofibrillary changes. A topographic study. , 1962, Archives of neurology.